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Clinical Review of Incretin Based Therapies: Their Role in the Management of Type 2 Diabetes Mellitus.   
Type 2 Diabetes has become an epidemic in the United States; a disease that according to the 
CDC, in 2013, was the 7th leading cause of death among Americans. Even though there are various 
treatments available, it is not very clear when these agents are appropriate for individuals. Some agents 
have unfavorable side effects and can cause hypoglycemia. Newer agents, incretin based therapies, offer 
an alternative to controlling hyperglycemia. These agents not only help lower Hemoglobin A1C (HbA1C) 
values, but they also have the added benefits of weight loss, blood pressure control, and very low risks of 
hypoglycemia. There are two classes of incretin based therapies, GLP-1 Agonists and DPP-4 Inhibitors.  
Though these treatments have been on the market for several years, the use and knowledge of these drugs 
is still not prevalent. This review will discuss the role of incretins in diabetes treatment, the unique 
benefits these agents offer, their therapeutic efficacy, safety, side effects and reasons why these agents are 
not being utilized. 
 
Background 
 Diabetes is a progressive disease that causes significant morbidity and mortality not only in the 
US but globally. An estimated 23.1 million Americans have diagnosed diabetes. The number of people 
with diabetes has quadrupled in the past 32 years (1980-2012), from 5.5 million to 21.3 million [1]. 
Globally every 6 seconds someone dies from complications related to diabetes, including cardiovascular, 
nephropathy, neuropathy and other organ complications [2].  The number of American adults diagnosed 
with diabetes each year has increased to 1.5 million new cases a year.  According to this growing trend, 
by 2050 1 out of 3 Americans will have diabetes.   
There are two types or forms of diabetes, Type 1 and Type 2.  For this review, type 2 diabetes is 
the focus. The morbidity associated with Type 2 Diabetes can be significantly reduced by early 
interventions that help reduce glucose levels to a nondiabetic range. Life style modification, weight loss, 
oral hypoglycemic agents, insulin and combination therapies are some of the treatment options available 
to help control hyperglycemia.   Even though there are a variety of therapeutic options for patients, the 
World Health Organization concluded that less than 50% of diabetics have well-controlled blood sugars 
on their current regimens. Cost, adverse side effects, lack of education on the long-term benefits, and 
medication administration, all play a major role in this deficit [1].   
3	
	
Newer agents known as “incretin” therapies, Glycogen Like Peptide Receptor Agonists and 
Dipeptidyl Peptidase 4, (GLP-1 and DPP-4), have proven to be effective in lowering glucose, are safe and 
provide unique benefits of weight loss, hypertension control and lipid reduction [3]. They have a lower 
incidence of hypoglycemia and have been proven to be as effective as other oral agents. They have 
effectively lowered HbA1C for patients not well controlled on monotherapy, when added to metformin 
[4]. They have also been proven to be as effective as other oral hypoglycemic agents as monotherapy 
when metformin is contraindicated [3].   Even with the added benefits and proven efficacy of incretin 
therapies, they are not being widely utilized by clinical providers.  Uncertainties about the use and safety 
increased when the US Food and Drug Administration released a statement that certain incretin treatments 
increased mortality [5].  In 2016, another meta-analysis concluded that there were no clear overall 
differences in mortality in any of the hypoglycemic agents [6]. This clinical review provides guidelines 
for when to initiate dual therapy, the efficacy of GLP-1 and DPP-4, their safety, adverse side effects and 
the unique benefits these agents can offer to a patient with uncontrolled diabetes.  
Epidemiology 
Type 2 diabetes is the most prevalent form of diabetes and accounts for 90-95% of adult 
diagnosed diabetes in the US. Globally, 415 million people have diabetes and  type 2 makes up 9-% of 
that population [2].  Americans 65 years of age or older are 25.2% more likely to have diabetes than 
younger Americans. In the US, American Indians, Hispanics, and African-Americans have a higher 
prevalence of type 2 diabetes.  Adults with less than a high school education had a higher prevalence of 
diabetes, 12.6% compared to 9.5% of people with high school diplomas and 7.2% of individuals with 
more than a high school education. Risk factors include smoking, obesity, physical inactivity, 
hypertension, hyperlipidemia, and hyperglycemia [2]. 
Pathophysiology 
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Diabetes is a chronic metabolic condition comprised of several contributing factors that result in 
the body’s inability to produce insulin, resistance to insulin action, and inadequate or excessive insulin 
secretion, all resulting in hyperglycemia. Approximately 50% of total daily insulin is secreted during 
basal periods, the remainder is secreted postprandially. The first phase of insulin secretion promotes 
peripheral consumption of the prandial load and usually occurs minutes after the consumption of a meal.  
During this phase, stored insulin is released and helps keep blood glucose from rising. If insulin storage is 
impaired, more time to produce insulin is required, which occurs during phase two. If phase two is still 
not able to control the high levels of glucose, this is considered impaired glucose tolerance. Blood glucose 
levels over 200 mg/dl after a meal is considered diabetes [2].  
Clinical Diagnosis of Type 2 Diabetes 
The American Diabetes Association (ADA) recommends that health providers start screening 
asymptomatic patients at >45 years of age, earlier if the patient has risk factors that increase their 
probability of acquiring diabetes.  Risk factors include: 1) obesity; 2) a first-degree family history of 
diabetes; 3) hypertension; or 4) hyperlipidemia.  One third of people with diabetes are asymptomatic and 
are unaware they have the disease.  Patients with low risk factors sometime learn they have diabetes 
during a routine glucose screening with their primary care providers. Blood tests, such as Fasting Plasma 
Glucose (FPG), and a 2-hour glucose tolerance test can be used to diagnose diabetes (see table 1).  The 
glucose tolerance test, however, is more inconvenient and expensive and is not used as often for clinical 
diagnosis. HbA1C is another blood test that can be monitored to measure the average amount of sugar in 
the bloodstream over the previous 90 days.  In the Early Diabetes Intervention Program, the study 
demonstrated that an HbA1C was more sensitive than a glucose tolerance test in the early detection of 
type 2 diabetes for at-risk individuals. In 2009 The International Expert Committee recommended the use 
of HbA1C as a diagnostic tool and in 2010 the ADA adopted this criterion [7].  Once a person has been 
diagnosed with diabetes and begins treatment, HbA1C can be used every three months to monitor 
response to therapy.  A HbA1C is an important indicator of how adequate a person’s glycemic treatment 
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and management is over a period of months. A HbA1C can also help identify when additional treatments 
may be indicated for more appropriate glycemic control [1]. 
 
The American Diabetes Association criteria for diabetes  
 
 
 
Targeted Glycemic Control 
The ADA defines the therapeutic target for HbA1C as <7.0%.  In order to achieve this HbA1C, a person’s 
blood glucose levels need to average 70 to 130 mg/dl before meals and less than 180 mg/dl two hours 
after starting a meal.  The level and duration of increased blood glucose in a diabetic increases the risk of 
diabetic complications. As glucose increases in the blood stream, the patient is in a state of 
hyperglycemia. Hyperglycemia can cause several complications for a diabetic. One serious condition that 
can occur due to hyperglycemia is ketoacidosis. Ketoacidosis can lead to seizures, coma and even death. 
Long term complications of diabetes include microvascular complications such as nephropathy, 
neuropathy, and retinopathy.  Macrovascular complications can also be a long-term effect of 
A	hemoglobin	A1C	
level	of	6.5%	or	
higher.
No	fasting	required
Fasting	Plasma	
glucose	of	126	mg/dL	
or	higher.
Fasting	is	required
A	2-hour	plasma	
glucose	level	of	≥	
200mg/dL	during	an	
oral	glucose	tolerance	
test
A	random	plasma	
glucose	of	≥200	
mg/dL	in	a	person	
with	classic	symptoms	
of	hyperglycemia	or	
hyperglycemic	crisis.	
Figure1	[1]	ADA	Criteria	for	Diabetes	
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hyperglycemia, including coronary artery disease, peripheral arterial disease, and stroke. It is because of 
the risk of these complications that is vital for patients to maintain adequate control of their blood 
glucose.  Lowering the target HbA1C at or below 7.0% has proven to help reduce both microvascular and 
macrovascular complications.  An estimated 5-10% of patient fail to maintain a targeted HbA1C of 7% 
per year, even after successfully initiating monotherapy [2].  
 
Guidelines for Initiation of Dual Therapy 
According to the ADA and European Association for the Study of Diabetes (EASD) guidelines, 
the addition of a second medication should be initiated when a patient fails to meet the goal of <7%, three 
months after a trial of both life style modifications and metformin.  Dual therapy should also be 
considered for all patients who have an HbA1C ≥ 9% [8]. Some type 2 diabetics can manage their 
diabetes with lifestyle changes, such as increasing physical activity and dietary modifications, to help 
with weight reduction.  Sustained weight loss has proven to help reduce the need for pharmacological 
therapy. Individuals are more successful at lowering their glucose if they have a minimum weight loss of 
7% of total body weight.  The Standard Care of Diabetes Journal also recommended a minimum of 150 
minutes of exercise per week to help achieve adequate weight loss [9 ].  Most type 2 diabetics are not able 
to control hyperglycemia with lifestyle modifications and require medications (Ref). Initial 
pharmacological therapy begins with an oral hypoglycemic agent such as metformin. Long standing 
evidence supports the use of metformin, a biguanide, as first line treatment for type 2 diabetes (ref). 
Metformin has proven safety and efficacy of reducing HbA1C, weight and cardiovascular mortality [10]. 
Not all patients can be effectively controlled on one therapy; eventually, because of the progressive nature 
of the disease, the use of an additional oral therapy or insulin is typically required.  
Table 1.  Comparison of medications for diabetes 
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Metformin 
 In 1995, Defranzo and his colleagues demonstrated the efficacy and tolerability of metformin. In 
their “protocol 1” 143 patients received metformin compared to 146 who received placebo. Those who 
took metformin had a lower mean fasting plasma glucose of 189 +/-5 mg/dl vs 244 +/-6 mg/dl. The 
	 	 	 	 	 	 	
Medication	 Initial	Dosing	 Side	Effects	 ALC	reduction	 Weight	Loss	 Other	Benefits	 Cost	
Biguanide	
MOS:	Inhibits	
glycogenosis	and	
gluconeogenesis.	
Metformin:	500	mg	
PO	BID	
								Or	
850	mg	PO	x	1	daily	
1.	Diarrhea	
2.		Lactic	Acidosis	
in	patients	with	
cardiovascular,	
renal	or	hepatic	
dysfunctions.	
3.	B12	deficiency		
1%	to	1.5%	 Weight	
neutral	
1.Reduces	CVD	events	
2.Prediabetes	treatment	
	<$20.00	a	
month	
Glucagon-like	
peptide-1	agonist	
MOA:	Decreases	
glucagon	secretion,	
slows	gastric	
emptying	and	
increases	satiety.			
	
	
	Albiglutide:	30mg	SC	
once	weekly	
Dulaglutide:	0.75mg	
SC	once	weekly	
Exenatide:	5mcg	SC	
BID	
Exenatide	XR:	2mcg	
SC	once	weekly	
Liraglutide:	0.6	mg	SC	
once	daily	x	1	week,	
then	1.2	mg	SC	once	
daily		
1.	Nausea	
2.Diarrhea	
3.Dosage	
modification	for	
renal	
dysfunction.	
4.Maybe	
associated	with	
pancreatitis	
5.Thyroid	cell	
cancer	in	rodents	
only		
	
1%	to	1.5%	 Weight	loss	 1.Decreased	risk	of	
hypoglycemia	as	
monotherapy	
2.Reduced	postprandial	
glucose	
3.Combination	injectable	
Albiglutide:	
$325	
Dulaglutide:	
$490	
Exenatide:	
$480	
Exenatide	
XR:$475	
Liraglutide:	
$430	
	
Dipeptidyl	Peptidase-
4	inhibitor	
MOA:	Prevents	
degradation	of	
endogenous	incretins	
increasing	insulin	
secretion	in	response	
to	elevated	glucose.	
Decreases	glucagon	
secretion	and	slows	
gastric	emptying.		
Aloglitin:	25	mg	PO	
once	a	day	
Linagliptin:	5mg	PO	
once	daily	
Saxagliptin:	2.5	or	5	
mg	PO	once	daily	
Sitagliptin:	100mg	PO	
once	daily	
	1.CYP3A4	
interactions	
2.Maybe	
associated	with	
pancreatitis	
	
0.5%	to	1%	 Weight	
neutral	
1.Well	tolerated	
2.Decreased	risk	
hypoglycemia	as	
monotherapy	
Aloglptin:	$310	
Linagliptin:	
$330	
Saxagliptin:	
$325	
Sitagliptin:$330	
. 
1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care2012;35:1364-79.	
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patients who received metformin had an average HbA1C value of 7.1% +/-0.1% compared to the placebo 
group of 8.6% +/-0.2% [10]. Overall metformin is still recommended as first line treatment for Type 2 
Diabetes by the ADA [12]. One of the biggest concerns for patients who are on metformin monotherapy 
is the gastrointestinal side effects. These side effects included diarrhea, dyspepsia, and flatulence.  One 
study showed that the extended form of metformin reduced the number of patients who experienced these 
side effects but did not resolve them for all patients. Several studies have investigated incretin therapies, 
both as secondary options for patients who cannot tolerate metformin and as dual therapy for uncontrolled 
diabetics currently on metformin monotherapy [10].  
Incretin Effect 
The incretin effect in the human body involves the body’s response to oral glucose that causes the 
increased insulin production in the body. The body’s homeostasis is regulated by a vast array of 
hormones, among those Glucagon-Like Peptide (GLP-1) and Gastric Inhibitory Polypeptide (GIP). The 
GLP-1 hormone is released from the small intestine when a meal is ingested, which triggers insulin and 
glucagon release to help regulate blood glucose. Oral glucose has a higher stimulatory effect on the 
production of insulin in comparison to intravenous glucose. GLP-1 hormones bind to receptors in the 
pancreas and trigger the beta cells in the pancreas to release insulin. They also signal alpha cells to 
decrease glucagon secretion and causes the liver to decrease the release of glucose.  Seventy percent of 
insulin secretion in a healthy human body comes from the incretin effect. GLP1 receptors can also be 
found in the hypothalamic center that controls energy intake.  In type 2 diabetes there is an impairment or 
loss of function of the incretin effect [30].  
GLP-1 Receptor Agonists 
     One of the more recently approved classes of therapeutic agents in the treatment of diabetes is 
incretin-based therapies. One of these therapies includes a GLP-1 receptor agonist. This medication works 
by binding to the receptors on GLP-1 when food enters the body and blood glucose levels rise.   Like the 
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naturally occurring GLP-1 hormone, the agonist works in the gut to slow gastric emptying, thereby 
slowing the amount of glucose that enters the body.  Delaying gastric emptying can help promote satiety 
and reduce the amount of caloric intake.  In the pancreas, it causes beta cells to increase insulin release 
and suppress glucagon secretion. In the liver, it decreases endogenous glucose production. The route of 
administration for GLP-1RAs is by injection, with a half-life of up to 13 hours in comparison to the 
body’s natural GLP-1 hormone’s half-life of 2 minutes.  The main role of the agonist is to increase 
resistance and time it takes dipeptidyl peptidase 4 to enzymatically degrade the glucagon-like peptide. 
These medications are only activated by the increase of blood glucose and reduce the overall chances of 
hypoglycemia [16].  Currently there are four FDA approved GLP-1 RAs, exenatide, liraglutide, exenatide 
LAR and albiglutide. Each has been studied as monotherapy and in combination with metformin.  
Short Acting GLP-1AR 
Exenatide was the first GLP-1 receptor agonist to be introduced in 2005 as an adjunctive 
treatment to diet and exercising for patients with Type 2 diabetes [15]. Exenatide therapy has been 
approved in the US to be used both as monotherapy and adjunctively with metformin. Exenatide helps to 
restore the first phase in insulin secretion and is administered prior to meals. It is not recommended for 
use after meals.  In one triple, blinded placebo controlled trial of 336 patients, exenatide 5 μg twice daily 
was added to treatment for patients already receiving metformin at a dose of 1500mg daily [15] The study 
concluded that an overall reduction of 0.78% +/- .10% in the HbA1C of those receiving exenatide 10μg, 
compared to those receiving metformin and placebo 0.08% +/- .10% and an overall weight loss of -2.8 
kg/+/- 0.5kg [15]. Of the 272 patients that completed the study 46% receiving 10 μg of exenatide twice 
daily achieved an A1C of ≤ 7% [15]. The most frequent side effects in the study were nausea, vomiting 
and hypoglycemia [15]. To help reduce nausea and vomiting a dose of 5 μg was recommended. To 
prevent hypoglycemia the injections should be administered at least 6 hours apart [15] In a 24 week, 
double blinded placebo-controlled, parallel-group study, exenatide was given to type 2 diabetes drug 
naive patients[18]. Patients were over the age of 18, maintained a diet and exercise regimen, were 
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randomly assigned to receive exenatide  5 μg exenatide 10 μg or placebo, each administered 
subcutaneously twice a day. At the end of the 24-week trial, exenatide was well tolerated[18 ] Patients 
sustained an improved HbA1C, reduced weight, improved blood pressure, and improved β cell function 
(REF). The authors concluded that it was an effective monotherapy option [21].   In another study 
comparing exenatide to metformin as monotherapy, exenatide has a greater reduction in HbA1C, -2.1 
mg/dl vs -1.6mg/dl and greater weight loss  -5.8kg vs -3.42kg[19] 
Liraglutide  
Liraglutide was the second GLP-1RA approved by the FDA in conjunction with lifestyle 
modifications. It has also shown efficacy in glycemic control both as monotherapy and in combination 
with metformin. Liraglutide delays absorption and resistance of DPP-4 degradation and is suitable for 
once daily administration independent of meal consumptions.  In a study by Garber, 746 patients with 
T2DM, received monotherapy with liraglutide 1.2mg and 1.8 mg daily, and effectively lowered HbA1c 
by -.84% and -1.4% [31].  In 2009 a study by Nauck, in which liraglutide 1.2mg and 1.8mg were given in 
combination with metformin daily versus glimepiride 4mg in combination with metformin, all three 
arms?resulted in a similar reduction of HbA1c of 1.0%. Liraglutide decreased body weight by -1.8kg to -
2.6kg compared to a 1.0 kg gain with glimepiride. Even though both these agents similarly decreased 
HbA1c, liraglutide had the added benefit of weight loss making it an ideal option for overweight or obese 
patients [20].  
Long Acting GLP-1RAs 
 Exenatide LAR and albiglutide have both been studied as monotherapy and in combination with 
metformin. In a 26-week randomized, double-blinded trial by Russel –Jones in which exenatide LAR 2mg 
was given subcutaneously weekly compared to Metformin 2,000mg daily, HbA1c was reduced by 
−1.53% with exenatide LAR, and –1.48% with metformin [21]. Weight loss was similar with both 
treatments, -2.0kg [21]. In a 52-week placebo-controlled study of diabetics not well controlled with diet 
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and exercise and not currently receiving pharmacotherapy, were randomized to receive albiglutide 30mg, 
50mg or matching placebo daily. At the end of week 52 patients receiving both 30mg and 50mg had a 
higher reduction in HbA1c compared to placebo. The most common side effects were injection site 
reactions [22]. 
DPP-4 –Inhibitors 
 Dipeptidyl Peptidase-4 is an enzyme the body naturally releases to inactivate both endogenous 
incretins, GLP-1 and GIP. DPP-4 is naturally released in order to maintain homeostasis and prevent 
hypoglycemia. DPP-4 enzymes regulate the amount of time incretins remain in the body. DPP-4 
inhibitors bind to active sites of DPP-4 enzymes and prevent the degradation of incretins.  By delaying 
the inactivation there is an increase of the sustained physiological action of incretins.  There are four FDA 
approved DPP-4 inhibitors, sitagliptin, saxagliptin, linagliptin, and alogliptin.  These drugs have proven 
to lower HbA1c both as monotherapy and in combination with metformin [23].  
 In a 24-week randomized double blind placebo controlled parallel group, type two diabetic 
patients with HbA1C range of 7.5-11% were randomized to receive one of 6 daily treatments. The 6 
regiments included sitagliptin 100 mg/metformin 1,000 mg (S100/M1000 group), sitagliptin 100 
mg/metformin 2,000 mg (S100/M2000 group), metformin 1,000 mg (M1000 group), metformin 2,000 mg 
(M2000 group) (all as divided doses administered twice daily [b.i.d.]), sitagliptin 100 mg q.d. (S100 
group), or placebo.  At the end of the trial sitagliptin reduced HbA1c in all the regiments, both as 
monotherapy and in combination with metformin with a decrease in baseline HbA1c of -0.83 (S100), -
2.07% (S100/M1000), and -1.57% (S100/M2000). The overall adverse reactions among the groups were 
only modestly different. The highest incidences of these occurred in the high dose metformin 
monotherapy group. The overall incidence of hypoglycemia was low and similar across all groups.  The 
one advantage that metformin had over sitagliptin was the weight reduction from baseline in patients         
-0.6—1.3 kg [24].  
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In a meta-analysis of randomized controlled trials, different DPP-4 inhibitors were compared to 
assess the effectiveness of reaching target HbA1c of 7% in patients with type 2 diabetes.  The meta-
analysis compared different arms in which each DPP-4 was used as monotherapy and in conjunction with 
metformin.  A total of 18 RCT, with 3,646 patients, testing sitagliptin showed that 37% of patients 
achieved HbA1c of <7% with no differences in the eight arms.  The mean decrease in HbA1c was .071%, 
-0.254 kg weight change and 3.1% incidence of hypoglycemia.  Nine RCT with 1,608, testing the efficacy 
of saxagliptin showed that 38% of the subjects achieved the target A1C <7 %. There were 3 arms that 
used saxagliptin at 5mg and 3 arms at 10mg. The mean decrease in HbA1c was 0.8%, with -0.20kg 
weight change and 3.4% incidence of hypoglycemia [25].   
 In a 24 week study by Del Prato et al., 503 patients were randomized to receive monotherapy 
with either linagliptin 5mg/day or placebo. At the end of the 24 weeks linagliptin achieved a significant 
decrease in HbA1c compared to placebo.  As monotherapy, the mean difference between the groups were 
-0.69%.  The study also assessed the postprandial glucose effects of linagliptin 30 minutes after meals for 
24 weeks.  The adjusted mean change was -33.5 mg/dl with linagliptin compared to an increase with 
placebo of 24.9 mg/dl and placebo-corrected mean change of -58.4 mg/dl significantly favoring the DPP-
4 inhibitor.  As adjunctive treatment with metformin, linagliptin had a significant change in HbA1c vs 
Treatment	
Number	of	
patients	
A1C<7%	 Adverse	reactions	 Hypoglycemia	
sitagliptin 50 mg/metformin 1,000 mg bid  178 66.00%	 105	 4	
sitagliptin 50 mg/metformin 500 mg bid 183 43.00%	 110	 2	
metformin 1,000 mg bid 177 38.00%	 113	 2	
metformin 500 mg bid 178 23.00%	 101	 1	
sitagliptin 100 mg q.d 175 20%	 96	 1	
Placebo 165 9%	 89	 1	
Table	2:		24-week	study	of	Sitagliptin	
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patients receiving metformin and placebo. The mean difference between groups was -.064%, and 
postprandial glucose was also assessed in this study and again showed a placebo-corrected mean of -67.1 
mg/dl in the linagliptin group [26].   
 Alogliptin also proved to have a significant reduction in HbA1c and monotherapy. In a 26-week 
double blind, placebo-controlled study drug naïve patients, were randomized to receive once-daily dosing 
of alogliptin 12.5 mg, alogliptin 25 mg, or placebo. Changes in HbA1c were noted as soon as week 4, at 
the end of the trial there was a significant decrease in the groups receiving alogliptin.  The group 
receiving 12.5 mg had a HbA1c reduction of -.56%, the 25-mg group had a decrease of -0.59% vs -0.2% 
reduction in the placebo group.  As an adjunct to metformin, alogliptin proved to be more effective in 
lowering the HbA1c when compared to monotherapy. The 26 week randomized double-blinded placebo 
controlled study evaluated the safety and efficacy of adding the treatment to patients already taking 
metformin. They were randomized by a 2:2:1 ration to receive metformin + either, alogliptin 12.5, 
alogliptin 25mg or placebo.  In the end both alogliptin groups lowered the A1c (-0.56% and -0.59%) 
greater than the placebo group (-0.2%) [27].  
Discussion  
 Even though the ADA does not recommend GLP-1RA or DDP-I as first line treatment, these 
medications have been approved as alternatives for patients who cannot tolerate metformin. These drugs 
have favorable effects on weight, blood pressure and lipids overall decreasing the risk for cardiovascular 
events. GLP-1RA can also be taken as once a week which can help increase patient adherence compared 
to metformin or an adjunct insulin based therapy. Even though DDP-4 inhibitors are more weight neutral 
they are still effectively reducing HbA1c as both monotherapy and as adjunct therapy and can be taken 
orally. Incretin treatments also help preserve beta cell function, a mechanism that other mediations fail to 
maintain. They have proven to be more effective in lowering HbA1c and decrease the risk of 
hypoglycemia. Like all medications, incretin-based therapies have reported side effects. The most 
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common side effects are nausea, vomiting, diarrhea and injection site reactions. Most of these side effects 
can be managed by titrating medications to reduce the overall incidence of adverse side effects. Acute 
pancreatitis has also been reported in patients who have been treated with both GLP-1RA and DDP-4 
inhibitors. Newer studies have shown that incretin-based treatments do not increase the risk of 
pancreatitis but there is an increased risk in patients who are obese with hypertriglyceridemia [11]. 
Medullary thyroid cancer (MTC) risk increases with GLP-1RA have been seen in rodents, but no cases 
have been proven in humans, and treatments are contraindicated in patients with personal or family 
history of MTC [29].   
Metformin is still recommended as the first line treatment for T2DM by the ADA. Metformin has 
proven efficacy in reducing cardiovascular events by reducing weight, cholesterol, and triglyceride 
concentration. Overall all-cause mortality has been significantly reduced with the use of metformin [26].  
Incretin therapies should be considered first line in patients who are not able to tolerate metformin. 
Incretins should also be considered as adjunctive therapy in uncontrolled metformin users, given their 
added benefits over other antidiabetic medications. They have proven to decrease the risk of 
hypoglycemia and can be taken daily or weekly, orally or by injection. Treatment should be tailored to 
meet the specific needs of each patient.  These drugs have a higher cost compared to other second line 
treatments like insulin, sulfonylureas or thiazolidinedione, making them less affordable. It is important to 
ensure insurance companies cover these drugs given that they are not found in generic forms at this time.  
Other things to consider in choosing a treatment includes dosing frequency and finding the appropriate 
time for these medications to be administered during periods of elevated glucose. The ease of how these 
medications are administered should also be considered.  Albiglutide and exenatide weekly require 
reconstitution before use.  Patients should be educated before the medications are prescribed to ensure the 
patient is able to complete these additional steps. To avoid toxicity these medications should also be 
titrated according to their recommended labeling.  
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Clinical inertia by practitioners continues to be a barrier in properly treating type 2 diabetics.  
Better management of type 2 diabetes among health care providers must be achieved by overcoming 
clinical barriers. Some of these barriers include: 1) time and resource constraints, 2) fear of hypoglycemia 
with more aggressive treatment, 3) failing to set clear patient goals, 4) lack of clear clinical guidelines, 5) 
lack of clear treatment strategies, and 6) lack of knowledge in new diabetes treatments, such as incretin 
based treatments.  Additional benefits of adding injectable incretin based therapies has been outweighed 
by providers in the belief that injectable medications are less acceptable in comparison to oral treatments. 
Improved awareness of newer therapies may help increase overall patient satisfaction and help patients to 
achieve HbA1c targets [29].  
Conclusion 
 Incretin therapies are effective agents for the treatment of type 2 diabetes. They offer a variety of 
advantages, including weight loss and beta cell protection and reduce the risk of hypoglycemia. They also 
have cardiovascular benefits by reducing blood pressure, lipids and weight.  They are also available in 
several forms of administration making them adaptable to personal lifestyles. Organizing a 
multidisciplinary team can help providers deliver a successful care plan and prevent clinical inertia. 
Patient adherence is linked to patient convenience, incretin based therapies have been designed to help 
address the complexity of these treatment regiments by combining multiple drugs in one pill or injection.  
Although these medications are proven effective as monotherapy and adjunctive therapy future studies are 
needed to define the long-term effect on safety and efficacy of these treatments and their impact on 
cardiovascular disease and mortality.  Future studies should also include guidelines for practitioners on 
how to effectively assess and mitigate the risks associated with these medications. 
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Appendix. 
Appendix table:  Risk of Bias in included studies (High, Inconclusive, or Low Risk of Bias) 
Study Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants & 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Reporting 
bias 
DeFronzo (2005) Low Low Low High High Low 
DeFronzo (1995) low High Moderate moderate Moderate Low 
Nauck (2009) Low Low Low Low Low Low 
Goldstein (2007) Moderate Low Low Low Moderate Low 
Garber (2009) Low Low Low Low Low Low 
Russell-Jones Low Low Low Moderate Low Low 
Nauck (2016) Low Low Low Low Low Low 
Capuano (2013) Low Low Low Low Low Low 
McGill Low Low Low Low Low Low 
DeFronzo (2008) Low Low Low Low Low Low 
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